Key Summary
- Maxwellia has launched Naprosyn® 250 mg OTС tablets for acute musculoskeletal pain—the first single-ingredient oral analgesic in this category in about a decade
- It’s opioid-free, non-steroidal, provides nearly 12 hours of relief, and is better than ibuprofen 400 mg and paracetamol for long-lasting pain control
- The company is supporting pharmacies with an online training platform for staff to ensure safe, effective use
Popular consumer healthcare company, Maxwellia, has rolled-out UK’s first over-the-counter naproxen medicine, Naprosyn® Pain Relief 250 mg gastro-resistant tablets.
It has been available in the market as a prescription drug over the last four decades.
It is the fifth brand of medicines that Maxwellia has brought into the pharmacies via reclassification.
They will provide pharmacies with naproxen as an OTC medication from next month, to manage acute musculoskeletal pain, with nearly 12 hours of pain relief.
This is a ground-breaking contribution by Maxwellia as it is the first OTC single-ingredient oral analgesic for acute back, muscle and joint pain in the past ten years.
There are 349 million packs of adult oral analgesics sold yearly for four out five people suffering from severe muscle and joint pain.
Musculoskeletal conditions are one of the most alarming health conditions in England, costing over 30 million working days every year and accounting for up to 30 per cent of GP consultations.
Compared to ibuprofen 400 mg, naproxen delivers much longer pain relief and offers superior 12-hour total pain relief compared to paracetamol.
The medicine is opioid-free, non-steroidal as well as an anti-inflammatory drug (ASD).
The company has also developed an effective online training platform www.naprosynpainrelief.com/hcp to provide pharmacy teams with appropriate training and pain resources, starting from today (September 15).
“In England alone, more than 7 million prescriptions are issued for naproxen each year for musculoskeletal conditions which underlines its trusted role in managing pain and inflammation,” spoke Anna Maxwell, Maxwellia founder and CEO.
“It’s because of this strong prescription heritage that pharmacy teams are already extremely familiar with both naproxen and the Naprosyn® brand.”
“In a recent survey, 95% of pharmacists were aware of the Naprosyn® brand,” she added.
“The addition of Naprosyn® Pain Relief to our pain management portfolio will provide patients with the choice of a powerful medicine to take control of their pain, and it is excellent news that we, as pharmacists, can now recommend it,” commented pharmacist and vice-chair of the National Pharmacy Association (NPA), Sukhi Basra.
Maxwell also added that, “This latest launch marks another key milestone in our mission to bring innovative medicines into pharmacies, supporting better self-care and empowering people to take greater control of their lives.”
